Patent US4532139A successfully refreshed from Google Patents.
US4532139A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compounds and compositions useful for producing analgesia
Assignee: Procter and Gamble Co
•
Filing: 1983-07-14
•
Granted: 1985-07-30
•
Expires: 2003-07-14
Abstract
Abstract Alkynamide compounds, and pharmaceutically-acceptable salts thereof, of the formula: <IMAGE> wherein X is O or S; R is straight or branched alkyne having from 11 to 23 carbon atoms; R1 is H, OH, or OCH3; R2 is OH or a short-chain ester; and wherein at least one of R1 and R2 is OH or OCH3. Compositions, useful for producing analgesia in humans or lower animals, comprise a safe and effective amount of: an alkynamide, pharmaceutically-acceptable salts thereof, or mixtures thereof; and a pharmaceutically-acceptable carrier. Preferably, these alkynamides are N-vanillyl-alkynamides. Methods of treatment, comprising administering a safe and effective amount of these alkynamides, pharmaceutically-acceptable salts thereof, or mixtures thereof, include methods of parenteral, oral, and topical administration.
Inventors
- 👤 John M. Janusz
- 👤 Thomas R. LaHann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 23:48
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K31/165; A61P; A61P25/00; A61P25/04; C; C07; C07C; C07C233/00; C07C233/01; C07C233/16
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
63 words
Alkynamide compounds and pharmaceutically-acceptable salts thereof, of the formula: ##STR6## wherein X is O or S; R is straight or branched alkyne having from 11 to 23 carbon atoms; R 1 is H, OH or OCH 3 ; R 2 is OH or a short-chain ester; and wherein at least one of R 1 and R 2 is OH or OCH 3 .
Claim 2
Dependent Claim
63 words
Alkynamide compounds and pharmaceutically-acceptable salts thereof, of the formula: ##STR6## wherein X is O or S; R is straight or branched alkyne having from 11 to 23 carbon atoms; R 1 is H, OH or OCH 3 ; R 2 is OH or a short-chain ester; and wherein at least one of R 1 and R 2 is OH or OCH 3 .
Claim 3
Dependent Claim
21 words
Alkynamide compounds, and pharmaceutically-acceptable salts thereof, according to claim 1, wherein R 1 is OCH 3 and R 2 is OH.
Claim 4
Dependent Claim
17 words
Alkynamide compounds, and pharmaceutically-acceptable salts thereof, according to claim 1, wherein R 2 is a short-chain ester.
Claim 5
Dependent Claim
15 words
Alkynamide compounds, and pharmaceutically-acceptable salts thereof, according to claim 2, wherein said alkynamide is N-vanillyl-9-octadecynamide.
Claim 6
Dependent Claim
91 words
A composition for producing analgesia in humans or lower animals, comprising: (a) a safe and effective amount of an alkynamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR7## wherein X is O or S, R is straight or branched alkyne having from 11 to 23 carbon atoms, R 1 is H, OH, or OCH 3 , R 2 is H, OH or a short-chain ester, and wherein at least one of R 1 and R 2 is OH or OCH 3 ; and (b) a pharmaceutically-acceptable carrier.
Claim 7
Dependent Claim
91 words
A composition for producing analgesia in humans or lower animals, comprising: (a) a safe and effective amount of an alkynamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR7## wherein X is O or S, R is straight or branched alkyne having from 11 to 23 carbon atoms, R 1 is H, OH, or OCH 3 , R 2 is H, OH or a short-chain ester, and wherein at least one of R 1 and R 2 is OH or OCH 3 ; and (b) a pharmaceutically-acceptable carrier.
Claim 8
Dependent Claim
20 words
A composition, according to claim 5, wherein R is straight or branched alkyne having from 16 to 21 carbon atoms.
Claim 9
Dependent Claim
17 words
A composition, according to claim 5, wherein R 1 is OCH 3 and R 2 is OH.
Claim 10
Dependent Claim
13 words
A composition according to claim 5, wherein R 2 is a short-chain ester.
Claim 11
Dependent Claim
27 words
A composition, according to claim 5, comprising a pharmaceutically-acceptable salt of said alkynamide compound, selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts.
Claim 12
Dependent Claim
20 words
A composition, according to claim 6, for parenteral administration, comprising at least about 90% by weight of said pharmaceutically-acceptable carrier.
Claim 13
Dependent Claim
21 words
A composition, according to claim 6, for oral administration, comprising from about 25% to about 50%, by weight, of said alkynamide.
Claim 14
Dependent Claim
19 words
A composition, according to claim 7, for producing analgesia in humans or lower animals, wherein said alkynamide is N-vanillyl-9-octadecynamide.
Claim 15
Dependent Claim
11 words
A composition, according to claim 8, wherein said alkynamide is N-[(4-acetoxy-3-methoxyphenyl)methyl]-9-octadecynamide.
Claim 16
Independent Claim
92 words
A method for producing analgesia in humans or lower animals, which comprises administering to said human or lower animal a safe and effective amount of an alkynamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR8## wherein X is O or S; R is straight or branched alkyne having from 11 to 23 carbon atoms; R 1 is H, OH, or OCH 3 ; R 2 is OH, or a short-chain ester; and wherein at least one of R 1 and R 2 is OH or OCH 3 .
Claim 17
Independent Claim
92 words
A method for producing analgesia in humans or lower animals, which comprises administering to said human or lower animal a safe and effective amount of an alkynamide compound or pharmaceutically-acceptable salt thereof, or mixtures thereof, of the formula: ##STR8## wherein X is O or S; R is straight or branched alkyne having from 11 to 23 carbon atoms; R 1 is H, OH, or OCH 3 ; R 2 is OH, or a short-chain ester; and wherein at least one of R 1 and R 2 is OH or OCH 3 .
Claim 18
Dependent Claim
24 words
A method, according to claim 14, wherein R of said alkynamide compound is straight or branched alkyne having from 6 to 21 carbon atoms.
Claim 19
Dependent Claim
11 words
A method, according to claim 15, wherein said alkynamide is N-vanillyl-9-octadecynamide.
Claim 20
Dependent Claim
12 words
A method, according to claim 15, wherein said alkynamide is administered intramuscularly.
Claim 21
Dependent Claim
12 words
A method, according to claim 15, wherein said alkynamide is administered orally.
Claim 22
Dependent Claim
12 words
A method, according to claim 15, wherein said alkynamide is administered topically.
References Cited (Backward Citations)
US3024281A
Cited
US2710299A
Cited
US2845449A
Cited
US3120434A
Cited
US3108038A
Cited
US3192213A
Cited
US3167556A
Cited
US3201401A
Cited
US3504028A
Cited
US3780103A
Cited
US4031186A
Cited
US4244730A
Cited
US4372972A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-07-29 | 1989-01-28 | 1989-07-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-07-29 | 1993-01-28 | 1993-07-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-07-29 | 1997-01-28 | 1997-07-30 | $7700.00 | Window Closed / Lapsed |